BioLineRx (BLRX) Issues positive Update on BL-8040 Phase 2 in r/r AML
Tweet Send to a Friend
BioLineRx (NASDAQ: BLRX) announced positive results from the dose escalation part of BL-8040’s Phase 2 clinical trial in relapsed or ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
